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Abstract   
Intravesical treatment of superficial bladder cancer with epirubicin is associated with 
local urological adverse effects, the causes of which are unknown. Our aim was to 
investigate the effects of epirubicin on the release of urothelial mediators and 
inflammatory cytokines. UROtsa cells were treated with epirubicin for 1 h at 37 °C. 
Release of urothelial transmitters and inflammatory cytokines was examined 
immediately, 24 h and 7 days following treatment. Release of ATP and nitric oxide 
were increased transiently after treatment with epirubicin (0.01mg/ml), but this was 
not evident one-week after treatment.  Basal prostaglandin E2 release was decreased at 
24 h but not at 7 days.  An increase in basal acetylcholine release and decrease in 
stretch-induced acetylcholine release were observed 24-h after treatment (0.01mg/ml). 
One week following epirubicin treatment (0.001 mg/ml), stretch-induced, but not 
basal acetylcholine release, was observed. Secretion of interleukin-6 and interleukin-8 
was increased 70-fold and 5-fold respectively, at 24 h (0.01mg/ml). This was 
sustained and one week after epirubicin treatment (0.001mg/ml), the increase in the 
secretion of both inflammatory cytokines was still evident.  
Epirubicin treatment induces several transient changes in urothelial function.  
However, the increased secretion of inflammatory cytokines (IL-6 and IL-8) is 
sustained and these mediators may be involved in the pathophysiology of bladder 
toxicity following intravesical epirubicin treatment.  
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1.0 Introduction 
Intravesical therapy is a widespread treatment approach for superficial bladder cancer 
and is undertaken due to a high recurrence rate (48 to 70%) of the disease after 
successful removal of bladder tumour (Logan et al., 2012). With intravesical 
treatment, high concentrations of cytotoxic agents can be administered directly into 
the bladder lumen to access the target cancer cells, whilst limiting systemic exposure 
(Dalton et al., 1991). Epirubicin, doxorubicin and mitomycin C (MMC) are 
commonly used agents for the treatment of superficial bladder cancer via this targeted 
means of delivery. Despite limited systemic side effects, there is evidence of 
significant local urological adverse effects such as chemical cystitis (dysuria, 
increased urinary frequency and urgency) following this treatment (Elmamoun et al., 
2014; Koya et al., 2006). 
 
The urothelium is in direct contact with the cytotoxic agents during intravesical 
treatment. While the urothelium serves as a distensible barrier to protect the 
underlying tissues from the potentially harmful contents of the urine, it also responds 
to bladder filling, by releasing a number of chemical transmitters including ATP 
(Burnstock, 2011a), acetylcholine (Birder, 2010), prostaglandin E2 (PGE2) (Tanaka et 
al., 2011) and nitric oxide (NO) (Winder et al., 2017).  These transmitters are 
involved in regulating sensory mechanisms and bladder contraction playing essential 
roles in maintaining normal bladder function. Despite the urothelium acting as an 
effective barrier to the movement of substances from the bladder lumen to the deeper 
tissue layers, previous studies have shown that some intravesical chemotherapeutic 
agents including doxorubicin and MMC diffuse into the detrusor muscle, although 
only at a fraction of the luminal concentration (Wientjes et al., 1996; Wientjes et al., 
1993).  
Our recent studies using RT4 cells have shown that the cytotoxic drugs doxorubicin 
(Kang et al., 2013) and mitomycin c (MMC) (Kang et al., 2015), alter the release of 
ATP, acetylcholine and PGE2 from urothelial cells immediately following treatment, 
as well as induction of pro-inflammatory cytokines and nitric oxide. Gemcitabine 
treatment produced comparable transient changes in urothelial ATP and PGE2 release, 
with sustained elevation in secretion of IL-6, IL-8 and IL-1β from UROtsa cells (Farr 
et al., 2017).  
 
Epirubicin is another cytotoxic drug that has been used for intravesical treatment of 
superficial bladder cancers. Whilst systemic adverse events after intravesical 
epirubicin have not been reported in many trials (Elsawy et al., 2019; Hendricksen et 
al., 2008; Onrust et al., 1999), major local urological adverse effects associated with 
treatment include chemical cystitis, haematuria and contracted.  Thus, the aim of this 
study was to investigate the effects of epirubicin on basal and stretch-induced release 
of urothelial transmitters from UROtsa human urothelial cells and determine whether 
changes in urothelial function may provide an explanation for the urological adverse 
effects experienced by patients treated with intravesical epirubicin. Inflammatory 
markers were also assessed to see if inflammation plays a role in the adverse effects 
associated with treatment. In addition, recovery of urothelial function was assessed 1-
week post-treatment. 
 
 
 
2.0 Materials and Methods 
2.1 Cell culture 
The UROtsa cell line was a gift from Dr. Scott Garret at the University of North 
Dakota. The cells were grown and maintained at 37°C in 5% CO2 in Dulbecco’s 
modified eagle medium (DMEM) (Sigma-Aldrich, St. Louis, USA). Low glucose 
culture medium contained 1mg/ml glucose (Sigma-Aldrich, St. Louis, USA), 1% v/v 
penicillin-streptomycin (Invitrogen, Victoria, Australia) and 5% v/v Foetal Bovine 
Serum (FBS) (Invitrogen, Victoria, Australia). Cell viability was assessed by trypan 
blue exclusion.  
 
2.2 Epirubicin treatment of urothelial cells 
UROtsa were maintained in serum-free medium from the time of seeding for 
experimental treatment to the end of the recovery period (Farr et al., 2017).  Twenty-
four-well plates were seeded at a density of 1.2×105 (for immediate effects and 24 h 
post-treatment effects) or 1.0×105 (for 1-week post-treatment effects) UROtsa cells 
per well and incubated overnight to allow cells to adhere.  
 
Cells were incubated at 37 °C for 60 mins with epirubicin (Tocris Bioscience, Bristol, 
UK) at concentrations up to 1 mg/ml (1.7 mM) diluted in serum-free DMEM culture 
medium, which is the clinical dose and duration used for intravesical therapy 
(Hendricksen et al., 2008). Cells were then used immediately, 24 h or 1 week later to 
generate samples for analysis of urothelial mediator release. During the 1-week 
recovery period, culture medium was changed every three days.  In experiments 
investigating recovery over 24 h and 1 week after treatment, only 2 concentrations of 
epirubicin were investigated (0.01 and 0.001mg/ml).  It has been reported that only 
small amounts of cytotoxic drug penetrate the urothelium (Wientjes et al., 1996) and 
therefore lower concentrations are more likely to reflect concentrations reached in 
urothelial cells in vivo.  
2.3 Mediator release from urothelial cells 
To determine the basal release of mediators, the cells were incubated for 15 min with 
isotonic solution (composition, mM: NaCl 130, KCl 5, CaCl2 1.5, MgCl2 1, NaHEPES 
25, BSA 0.015 and glucose 5). Then, the solutions on the plate were aspirated and 
fresh isotonic solution was added into each well. After 10 min, the solutions in each 
well were collected for the measurement of basal mediator release from epirubicin-
treated and control cells.  
For hypo-osmotically stimulated (stretch simulation) release of urothelial mediators, 
hypotonic solution (isotonic solution without NaCl) was added into each well. After 
10 min incubation, the solutions in each well were collected for analysis of urothelial 
mediators. The use of hypotonic solution causes the cells to swell, mimicking the 
stretch that occurs during bladder filling (Kang et al., 2013, 2015).  
2.4 Resazurin viability assay  
Reduction of the redox dye resazurin to resorufin was used to measure the viability of 
cells (Farr et al., 2017). Cells were seeded in 96-well microtiter plates 24 h prior to 
the addition of epirubicin (0-1 mg/ml) for 1 h at 37 °C. After incubation with 
epirubicin, treatment medium was removed, and cells were washed twice with PBS 
solution prior to performing the resazurin reduction cell viability assay. While 
immediate effects of epirubicin on urothelial cell viability was assessed instantly after 
removing treatment medium and washing with PBS solution, the viability of cells 24 
h or 1 week following epirubicin treatment was measured after maintaining cells with 
fresh serum-free culture medium at 37 °C. The resazurin reduction cell viability assay 
was performed by incubating cells for 1 h with fresh medium containing 44 μM 
resazurin. After 1 h incubation, reduction of resazurin to resorufin was determined by 
fluorescence (excitation 530 nm; emission 590 nm) using a Modulus microplate 
reader. Appropriate cell-free controls were also included. Under all conditions tested, 
the extent of resazurin reduction was directly proportional to viable cell counts (data 
not shown).  
2.5 Measurement of urothelial mediators 
Release of ATP was measured using an ATP determination kit (Molecular Probes). 
Luminescence was measured using a Modulus microplate reader (Promega). 
Acetylcholine was measured using the Amplex® Red Acetylcholine Assay kit 
(Molecular Probes). Fluorescence was measured on a Modulus Microplate reader (Ex. 
540/Em. 590 nm). The level of prostaglandin E2 released from UROtsa cells was 
measured using the Prostaglandin E2 EIA (Cayman Chemicals). Samples and 
standards were analysed using a Modulus microplate reader (420 nm). All assays 
were conducted according to manufacturer’s instructions and ATP, Acetylcholine and 
PGE2 concentrations were normalised to controls using corresponding resazurin 
reduction data.  
2.6 Inflammatory cytokine analysis 
Cell-free incubation medium was collected from T25 culture flasks 24 h and 1 week 
after epirubicin pre-treatment. The presence of inflammatory cytokines (IL-8, IL-1β, 
IL-6, IL-10, IL-12p70 and tumour necrosis factor, TNFα) was analysed using a 
BDTM Cytometric Bead Array Human Inflammatory Cytokines Kit. Standard and 
sample fluorescence were determined on a BDTM FACS Calibur flow cytometer. 
Concentrations of inflammatory cytokines were normalised to controls using 
corresponding resazurin reduction data.  
2.7 Nitrate/nitrite analysis 
Cell-free incubation medium was collected from T25 culture flasks 24 h and 1 week 
after epirubicin pre-treatment. Release of urothelial nitric oxide into the incubation 
medium was assessed by measuring its metabolites nitrate and nitrite using a 
Nitrate/Nitrite Fluorometric Assay Kit (Cayman Chemicals). Fluorescence was 
measured on a Modulus Microplate reader. Nitrate/nitrite concentrations measured 
were normalised to controls using corresponding resazurin reduction data.  
2.8 Statistical analysis 
Results are expressed as mean ± standard error of the mean (S.E.M.).  Data were 
analysed using a paired Student’s t test or one-way ANOVA with Dunnett multiple 
comparisons test, using GraphPad InStat3 software (San Diego, CA). Significance 
levels were defined as P < 0.05 (*), P < 0.01 (**) and P < 0.001 (***).  
 
 
 
 
 
 
 
 
 
 
3.0 Results 
3.1 Effects of epirubicin on urothelial viability and release of mediators 
Urothelial cell survival following treatment with epirubicin at concentrations ≥ 0.01 
mg/ml was significantly reduced all time points tested post-treatment with complete 
cell death observed in cells treated with 1 mg/ml epirubicin compared to control cells 
at all time points (Fig. 1).     
The urothelial cells released ATP under basal conditions and cell stretch induced with 
hypotonic solution significantly increased release by approximately 8-fold (controls in 
Fig. 2A-B). The cells also released acetylcholine with basal concentrations reaching 
levels 100-fold greater than those observed with ATP.  Stimulation with hypotonic 
solution again further increased levels by approximately 5-fold (controls in Fig. 2C-
D).  PGE2 release was also observed, but at much lower levels (only 10% of that to 
ATP), but again stimulation of cells increased release in this case by about 10-fold 
(controls in Fig. 2E-F). 
Immediately following treatment at the clinical dose (1 mg/ml), complete cell death 
was observed and urothelial mediator release could not be measured in cells treated 
with this concentration. However, treatment with lower concentrations of epirubicin 
were examined and the release data corrected for changes in cell number. Epirubicin 
had no effect on basal or stimulated release of mediators at low concentration but did 
enhance both basal and stimulated release of ATP at 0.1mg/ml (Fig. 2 A&B).  
Acetylcholine and PGE2 were unaffected by treatment with epirubicin at any 
concentration (Fig. 2 C-F). 
Since urothelial ATP release was affected immediately after epirubicin treatment, the 
ability of the urothelium to recover was assessed. Release of urothelial mediators was 
measured 24 h after epirubicin treatment with low epirubicin concentrations (≤ 0.01 
mg/ml) as these concentrations are likely to be more relevant since only a small 
fraction of intravesical chemotherapeutic agents penetrates the urothelium(Wientjes et 
al., 1996; Wientjes et al., 1993).  Both basal and stimulated release of ATP from 
urothelial cells treated with 0.01 mg/ml epirubicin increased significantly compared to 
vehicle-treated controls 24 h following treatment, with basal levels increasing 7-fold 
and stimulated levels increasing 2-fold (Fig. 3A-B). While basal release of 
acetylcholine was significantly increased in cells treated with 0.01 mg/ml epirubicin, 
the increase was only 30%, and the opposite occurred with stimulated levels of 
acetylcholine where the same concentration of epirubicin depressed release by almost 
70% (Fig. 3C-D).  Basal PGE2 release was significantly reduced in cells treated with 
0.01 mg/ml epirubicin at 24 h (Fig. 3E).  However, stimulated release of PGE2 
remained unchanged compared to control cells 24 h following epirubicin treatment 
(Fig. 3F). 
 
One week after treatment with 0.001mg/ml epirubicin, basal levels of ATP and 
acetylcholine were unaffected, but stimulated release for these two mediators was 
changed by epirubicin treatment but with opposite effects: stimulated ATP levels 
were reduced whilst those to acetylcholine were increased (Fig. 4).  As previously, 
basal PGE2 release was unaffected by epirubicin treatment. It should be noted 
however that hypotonic stimulation prostaglandin E2 response over basal was no 
longer present at this timepoint (Fig. 4E and F). 
 
Effects of epirubicin on inflammatory cytokine and nitric oxide release 
As a measure of urothelial inflammation, the presence of inflammatory cytokines IL-8, 
IL-1β, IL-6, IL-10, IL-12p70 and TNFα in urothelial cell incubation medium was 
tested 24 h and 1 week after epirubicin treatment. Neither IL-1β, IL-6, IL-10, IL-
12p70 nor TNFα were detected in control or treated samples at any timepoint. 
However, IL-6 was secreted by untreated urothelial cells at 24 h, while urothelial cells 
treated with epirubicin (0.01 mg/ml) showed a 70-fold increase in release of this pro-
inflammatory cytokine (53.24 ± 5.02 pg/ml control vs. 3511 ± 494 pg/ml treated, 
P<0.01) (Fig. 5A). IL-8 was also secreted by untreated urothelial cells at 24 h, and 
treatment with epirubicin (0.01 mg/ml) resulted in a 5-fold increase in release (292 ± 
23 pg/ml control vs. 1519 ± 89 pg/ml treated, P<0.01) (Fig. 5C). One week after 
epirubicin treatment the release of IL-6 and IL-8 continued to be elevated compared 
to controls (IL-6, 8-fold increase, P<0.001; IL-8, 3-fold increase, P<0.001) (Fig. 5B). 
To determine the effects of epirubicin on urothelial nitric oxide release, nitrate and 
nitrite (metabolites of nitric oxide) were measured in incubation medium. Nitric oxide 
was released by untreated UROtsa cells at 24 h, with a significant increase observed 
from UROtsa cells treated with epirubicin (0.01 mg/ml, Fig. 5E), but 1 week after 
treatment no significant differences could be detected compared to control (Fig. 5F). 
 
 
 
 
 
 
 
 
 
 
4.0 Discussion 
The present study investigated the effects of the intravesical chemotherapeutic agent, 
epirubicin on urothelial function, markers of inflammation and the ability of urothelial 
function to recover following epirubicin treatment.  
It is well established that in normal bladder, the release of ATP from the urothelium 
acts on purinoreceptors (P2X2/3) present on sensory nerves to initiate the micturition 
reflex and to give rise to perception of pain through low threshold Aδ-fibres and high 
threshold C-fibres respectively (Burnstock, 2011b).  In addition, ATP can act directly 
on the detrusor muscle causing bladder contraction (West et al., 2018). Intravesical 
epirubicin treatment causes urological adverse effects such as painful urination and 
urgency, so it was notable to find elevation of both basal and stimulated ATP release 
immediately after epirubicin treatment (0.1 mg/ml), which was still evident 24 h 
following treatment. An increase in stretch-induced urothelial ATP release has been 
reported in a number of disorders of the bladder including idiopathic and neurogenic 
bladder overactivity and painful bladder syndrome (Kumar et al., 2007; Takezawa et 
al., 2017).  Thus, the initial enhancement of ATP release suggests that this mechanism 
could directly contribute to the initial pain and bladder overactivity reported in 
patients treated with intravesical epirubicin. However, in our study, elevated ATP 
levels were not maintained and one week after treatment, levels were actually 
depressed, suggesting that the changes in ATP are not responsible for these symptoms 
in the longer term.  The decrease in stretch induced ATP release, 1 week following 
treatment may reflect changes in adenosine, which has previously been reported to 
inhibit distension-induced ATP release via activation of the A1 receptor (Dunning-
Davies et al., 2013).  
Urothelial acetylcholine can exert effects on detrusor and sensory nerves, although its 
role in regulating bladder function is not as clear as that for ATP.  Acetylcholine can 
contract detrusor smooth muscle, but whether concentrations reaching the muscle 
from the urothelium are great enough to influence contraction is not known.  The 
urothelium itself expresses muscarinic receptors and the acetylcholine released during 
stretch has been shown to stimulate pacemakers in the lamina propria to increase the 
spontaneous rate of phasic contractions (Moro et al., 2011), which may ultimately 
lead to increased detrusor activity and hence overactivity. Acetylcholine also 
influences sensory nerve activity but again there are conflicting reports with both 
stimulation and inhibition of nerve activity being reported (Daly et al., 2010).  Thus 
the role of acetylcholine in bladder function has not been fully elucidated but overall 
it increases bladder contractile activity and this underlies the use of muscarinic 
antagonists in the treatment of bladder overactivity (Kumar et al., 2003). Following 
urothelial cell treatment with epirubicin, there was a transient decrease in 
acetylcholine release at 24 hours post-treatment, which was reversed to a more than 2-
fold elevation of release one week after treatment, which could possibly contribute to 
symptoms of overactivity in patients. 
The role of urothelial-derived PGE2 in bladder function is not well understood, but 
inhibition of cyclooxygenase improves storage function in rats with detrusor 
overactivity, indicating potential stimulatory effects of PGE2 on the micturition reflex 
(Yokoyama, 2010).  This is supported by a report that over-expression of PGE2 in 
mice results in bladder overactivity via PGE2 activation of C-fibres (Aoki et al., 2009; 
Maggi et al., 1988).  In our study, epirubicin had no effect on either basal or 
stimulated release of PGE2 from UROtsa cells immediately, or 1-week post-treatment; 
however, a minor decrease in basal release was observed at 24 h. Therefore, like other 
intravesical chemotherapeutic agents tested previously doxorubicin, gemcitabine and 
MMC; epirubicin also results in alterations in PGE2 release from urothelial cells, 
although transiently (Farr et al., 2017; Kang et al., 2013, 2015).  The changes in PGE2 
release following epirubicin treatment may be reflective of concurrent changes in 
ATP release, as regulation of these urothelial mediators are thought to be correlated 
(Tanaka et al., 2011). 
The link between release of inflammatory mediators and intravesical cytotoxic agents 
such as Bacillus Calmette-Guerin (de Boer et al., 1997) and doxorubicin (Abou El 
Hassan et al., 2003) has been reported previously and studies have also shown that 
mitomycin C induces release of IL-8 in human fibroblasts (Chou et al., 2007).  In the 
present study, increases in IL-8 and IL-6 were observed 24 hours following epirubicin 
treatment, and both inflammatory cytokines remained elevated 1week after treatment.  
Inflammation has been shown to increase bladder afferent excitability and is believed 
to contribute to bladder overactivity and pain (Hayashi et al., 2009). IL-8 and IL-6 
play important roles in the generation and propagation of chronic inflammation: IL-8 
attracts neutrophils to the site of inflammation (Petering et al., 1999), whilst IL-6 
increases the expression of endothelial leukocyte adhesion molecules thus promoting 
leukocyte accumulation (Barnes et al., 2011; Rose-John, 2012) and rescues T cells 
from apoptosis, which promotes a chronic inflammatory cell infiltrate (Curnow et al., 
2004; Narimatsu et al., 2001). A recent study has suggested that inflammation may be 
a key factor in the development of bladder overactivity, where increased levels of pro-
inflammatory cytokines including IL-6 and IL-8 were detected in a chronic bladder 
ischemia model of overactivity (Nomiya et al., 2012). 
Inflammatory cytokines have been also demonstrated to be elevated in our previous 
cytotoxic drug studies, where urothelial cells were treated with either mitomycin C or 
doxorubicin. An increase in IL-8 from RT4 urothelial cells 24 h and 1 week after 
initial mitomycin C treatment (Kang et al., 2015). In addition, doxorubicin treatment 
induced the release of IL-8 and IL-1β from RT4 cells 24 h following treatment (Kang 
et al., 2013). Thus, our data suggests that the induction of inflammatory cytokines and 
their persistent release are common to chemotherapeutic agents such as doxorubicin, 
MMC and epirubicin and therefore may play a significant role in development of the 
bladder overactivity and pain experienced by patients following intravesical 
chemotherapeutic treatment. In addition, the decrease in stimulated release of ATP 
one week after the treatment reported here may be due to the effects of inflammatory 
cytokine release by epirubicin treatment, since a study by Mansfield & Hughes (2014) 
demonstrated that exposing human urothelial cells to inflammatory mediators 
(histamine and serotonin) resulted in reduced stretch-induced release of ATP.   
Nitric oxide along with acetylcholine is co-released from parasympathetic nerves and 
exerts an inhibitory effect on smooth muscle contraction (Dokita et al., 1991), but the 
urothelium is an another source of NO in the bladder (Birder et al., 1998; Giglio et al., 
2005).  The role of urothelial-derived NO in bladder function is uncertain. However, 
some indirect evidence suggests its potential function in modulation sensory nerve 
activity (Giglio et al., 2005) and nitric oxide donors have been shown to have 
inhibitory effects on afferent nerve activity (Aizawa et al., 2011), urothelial 
contraction (Moro et al., 2012) and pacemaker activity (Moro et al., 2012).  Increased 
levels of nitric oxide have been reported with inflammatory diseases of the bladder 
and after intravesical immunotherapy for bladder cancer (Ehren et al., 1999; 
Logadottir et al., 2004).  A study involving bladder cancer patients treated with 
Bacillus Calmette-Guerin has shown localisation of inducible nitric oxide synthase 
(iNOS) expression on the urothelium (Koskela et al., 2008). Also, increased NOS 
expression and enhanced nitric oxide release from the bladder are associated with 
cyclophosphamide-induced cystitis (Andersson et al., 2008; Aronsson et al., 2014). 
Increased nitric oxide production in the bladder wall has been reported in patients 
with interstitial cystitis, with a concurrent increase in IL-6 mRNA (Logadottir et al., 
2014). 
Several studies have assessed the impact of anthracyclines (including doxorubicin and 
epirubicin) on NO signalling pathways, in particular in relation to the cardiotoxicity 
associated with these agents. In the heart, exposure to these drugs increases 
myocardial iNOS expression resulting in enhanced NO production (Pacher et al., 
2003; Weinstein et al., 2000).  The present study has demonstrated an increase in NO 
release from UROtsa cells 24 h after epirubicin treatment. This is consistent with the 
effects of MMC on RT4 urothelial cells, however the levels returned to normal 1-
week following epirubicin treatment unlike in MMC treated cells where the changes 
in NO release were still evident 1 week later (Kang et al., 2015). These findings 
suggest that an initial increase in NO is common to both MMC and epirubicin 
treatment, but recovery to normal levels may be time dependent. These also reflect 
why side-effects are more commonly reported following MMC treatment compared to 
other intravesical drugs (Shelley et al., 2012).  
Hence, the increase in NO release 24 h following epirubicin treatment may initially 
contribute to alterations in bladder function experienced in patients treated with 
intravesical epirubicin, but as there is recovery after 1 week following the treatment, it 
is likely that the direct effects of changes in nitric oxide in patients treated with 
intravesical epirubicin is short- rather than long-term.  
 
 
5.0 Conclusion 
In conclusion, the effects of intravesical agents on tumours are well understood, but 
their safety profiles have received less attention. Due to the targeted delivery method, 
systemic side effects are rare following intravesical treatments, however, local urinary 
adverse effects are frequently reported.  The results of this study suggest that while 
alterations in urothelial mediator release (ATP, acetylcholine and NO) could 
contribute both transiently and long-term to local adverse effects experienced by 
patients treated with epirubicin, the most likely mechanism causing adverse effects is 
the induction of urothelial inflammatory cytokine release which is sustained and has 
been reported to be strongly associated with development of bladder dysfunction such 
as bladder pain and overactivity. 
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Fig. 1: Effect of 1 h epirubicin treatment on urothelial cell viability assessed by resazurin 
reduction immediately [A], 24 h [B] and 1 week [C] after treatment. Data are expressed as 
means ± S.E.M. (N=6). **P<0.01 and ***P<0.001 compared to vehicle control cultures. 
 
Fig. 2: Immediate effects of 1 h epirubicin treatment on basal extracellular ATP [A], 
acetylcholine [C] and prostaglandin E2 [E] concentrations, and ATP [B], acetylcholine [D] 
and prostaglandin E2 [F] responses to hypo-osmotic stimulation. Data are expressed as means 
± S.E.M. (N=6). **P<0.01 compared to vehicle control. 
 
Fig. 3: Twenty-four-hour post-treatment effects of epirubicin on basal extracellular ATP [A], 
acetylcholine [C], PGE2 [E] concentrations, and ATP [B], acetylcholine [D] and PGE2 [F] 
responses to cell stretch. Data are expressed as means ± S.E.M. (N=6). *P<0.05 and **P<0.01 
compared to vehicle control. 
 
Fig. 4: One-week post-treatment effects of epirubicin on basal extracellular ATP [A], 
acetylcholine [C], PGE2 [E] concentrations, and ATP [B], acetylcholine [D] and PGE2 [F] 
response to cell stretch. Data are expressed as means ± S.E.M.. *P<0.05 compared to vehicle 
control. 
 
Fig. 5: IL-6 secreted from control and epirubicin treated urothelial cells 24 h [A] and 1 week 
[B] after treatment. IL-8 secreted from control and epirubicin treated urothelial cells 24 h [C] 
and 1 week [D] after treatment. Nitrite/nitrate released from cells 24 h [E] and 1 week [F] 
following epirubicin treatment.  Data are expressed as means ± S.E.M. (N=6). **P<0.01 and 
***P<0.001 compared to vehicle control. 
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